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CAUSES AND PREDICTION OF RE-ADMISSIONS OF HEART FAILURE PATIETS 
Sudha mallika J1, Rajasekaran S2 
OBJECTIVE /AIM:  
The purpose of the study to predict individual’s risk for hospital readmission for congestive heart 
failure using data available at the time of index hospital discharge 
MATERIALS AND METHODS 
            Patients admitted for heart failure previously in madras medical college and 
Rajiv Gandhi government general hospital and now readmitted with history of heart failure 
symptoms within the 3 months of discharge are included in the study. Total sample size is 98. 
The study period is April 2014 – September 2014. . As this study is both prospective and 
retrospective the lab parameters and clinical parameters of patients previously admitted are 
obtained from medical records department, Rajiv Gandhi government general hospital.  
RESULTS 
In our study showed 60% of males and 40% females in medical wards. 40-55 age group showed 
44.8% of readmission incidence, 5-9 DAYS of previous admission stay showed 45.91% of 
readmissions. 35.7% of patient had coronary artery disease as underlying cause. 26.5% had 
diabetes mellitus as most common comorbid illness. 15.3% has lack of compliance as 
precipitating factor. 
CONCLUSION 
The inferences attained from the study are 
1. Readmissions are common in the younger age group patients 
2. Underlying causes are correctable by surgical measures 
3. Use of drugs that decrease the disease progression not used appropriately as there is lack 
of compliance and awareness 
4. Diabetes mellitus and heart failure commonly are associated in many patients 
5. Severe left ventricular systolic dysfunction and diastolic dysfunction is the most common 
echocardiogram finding associated 
KEY WORDS 
Heart failure, readmissions, ACE inhibitors, diabetes mellitus 
1. Postgraduate  institute of internal medicine RGGGH Chennai 
2.  Professor of institute of internal  medicine RGGGH Chennai 
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INTRODUCTION 
 
 Heart failure is a worldwide problem and the principal 
complication of all heart disease.  Approximately one-half of the patients 
have moderately to severely reduced LV systolic function, and 50 to 76 
percent of patients admitted with acute heart failure had a prior history of 
heart failure.  
Despite dramatic improvement in outcomes with medical therapy, 
admission rates following heart failure hospitalization remain high, with 
≥50% patients readmitted to hospital within 6 months of discharge. 
Recurrent heart failure and related cardiovascular conditions account for 
only about half of readmissions in patients with heart failure, whereas 
other comorbid conditions account for the rest. Individually, several 
physiological indices of heart failure severity do anticipate higher event 
rates. Many correlate strongly with elevated filling pressures, such as 
jugular venous pressure, orthopnea, and echocardiographic filling 
patterns.  
 Given the impact of high readmission rates to hospitals, it is 
important for individual hospitals to identify which patients may be at 
highest risk of being readmitted. 
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 Certain risk factors, such as patient age, race, diagnoses, length of 
stay (LOS), comorbidities, insurance, disposition, and prior 
hospitalizations, are well-documented. Our study aims at predicting the 
individual’s risk for hospital readmission for congestive heart failure 
using data available at the time of index hospital discharge. 
  
  
 
 
 
AIMS AND OBJECTIVES 
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AIM & OBJECTIVES 
 The purpose of the study to predict individual’s risk for hospital 
readmission for congestive heart failure using data available at the time of 
index hospital discharge 
 
PRIMARY OBJECTIVE:  
 The purpose of the study to predict individual’s risk for hospital 
readmission for congestive heart failure using data available at the time of 
index hospital discharge 
 
SECONDARY OBJECTIVE(S): 
 To study the demographic characteristics of the patients. 
 To analyze the patient’s treatment pattern and follow-up 
arrangements. 
 To determine the underlying and precipitating causes of their 
illness and therefore readmission. 
 To assess the knowledge, attitude and participatory qualities of the 
patients and their contribution to the readmission. 
 
 
  
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
 
ACUTE HEART FAILURE SYNDROME 
 It can be defined as the new onset or recurrence of symptoms 
developing gradually or rapidly, signs requiring urgent or emergent 
treatment and resulting in hospitalization 
EPIDEMIOLOGY 
 The magnitude of heart failure is difficult to assess with accuracy 
as the population based study of its incidence,  prevalence, and prognosis 
are lacking1. The prevalence of  heart failure increases with age. Risk was 
prospectively estimated to be 62%, 17%, 10%, 8%, 3%, 2% for coronary 
artery disease, cigarette smoking, hypertension, obesity, diabetes mellitus, 
and valvular heart disease respectively in US. Rheumatic cause of cardiac 
disease remains a major cause of heart failure in Asia and Africa. As 
socioeconomic development going on in developing countries like Asia, 
the epidemiology of heart failure similar to that of  western society 
 
CLASSIFICATION 
EUROPEAN SOCIETY OF CARDIOLOGY GIDELINES 
1. New onset or de novo heart failure; present for first time with 
symptoms of heart failure or they may not have prior history or 
have risk factors for heart failure (HF stage A according to ACC/ 
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AHA guidelines)or pre-existing structural heart disease(heart 
failure stage B according to ACC/AHAguidelines). Most of them 
develop AHFS in the setting of acute coronary syndromes. 
2. Worsening chronic HF; patients have prior history of chronic heart 
failure(HF stage C according to the ACC/ AHA guidelines) and 
with decompensation episode. This is about 80% of patients 
hospitalized with AHFS. Triggering event may be severe chronic 
symptoms than by an abrupt change in clinical condition 
Clinical scenarios at the time of presentation  
1. Clinical pulmonary edema 
2. Hypertensive heart failure 
3. Cardiogenic shock 
4. Isolated right sided heart failure 
5. Acute coronary syndrome and heart failure 
6. Worsening or decompensated chronic heart failure 
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ETIOLOGIES OF HEART FAILURE WITH DECREASED 
EJECTION FRACTION2 
 
 
PATHOPHYSIOLOGY 
1. NEURO HORMONAL ACTIVATION 
2. LEFT VENTRICULAR REMODELLING 
Are the primary determinants in disease progression 
Heart failure occurs after a primary event like myocarditis which 
leads to loss of normal force of cardiac contractrility which 
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damages cardiac muscles.  Substrate refers to cardiac structure and 
function. The underlying substrate may be  of normal ventricular 
function, for example, patients without a prior history of HF who 
develop AHF because of sudden changes in ventricular function 
from an insult example  myocardial infarction . Alternatively, some 
patients may have no prior history of HF but abnormal substrate 
(e.g., stage B patients which is asymptomatic LV dysfunction) with 
a first presentation of HF (de novo HF). Finally, most patients with 
AHF have a substrate of chronic compensated HF and then develop 
decompensation. 
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SCHEMATIC REPRESENTATION OF PATHOPHYSIOLOGY OF 
HEART FAILURE 
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ACTIVATION OF SYMPATHETIC SYSTEM 
 
1. In heart –there is desensitization of beta receptors, myocyte 
hypertrophy, necrosis , apoptosis and fibrosis 
2. Kidney- reactivation of RAS leading to increased salt and water 
retention and reduce response to natriuretic factors 
3. Peripheral vessels- neurogenic vasoconstriction  and vascular 
hypertrophy 
  
  
2. ACTIVATION OF THE RENIN ANGIOTENSIN
 
 
 
RAS activation in heat failure occurs comparatively later than the 
activation of  SNS
occurs as a result of: 
 
1. Decreased 
2. sympathetic activity
3. reduced sodium that is filtered 
 
10 
.  Mechanism of RAS activation in heart failure
 
renal perfusion 
 
reaching macula densa
 
 SYSTEM3 
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ANGIOTENSIN SYNTHESIS AND DEGRADATION 
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 Systemic and tissue components of renin-angiotensin system 
Angiotensin II exerts its effect through two receptors. 
  
1. AT1  receptors activation leads to vasoconstriction, aldosterone 
secretion, cell growth and catecholamine release. It is predominant 
in the vascular tissue 
2. AT2 , activation of this receptors causes vasodilation, natriuresis, 
inhibition of cell growth and bradykinin releas. In myocardium 
AT2 receptors are predominant in 2: 1 molar ratio. 
3. In heart failure AT1 down regulated resulting in the ratio of AT1 to 
AT2 recptors to decrease 
 
ALDOSTERONE SECRETION`4 
 Aldosterone secreted from zona glomerulosa of adrenal cortex by  
the action of angiotensin II. It promotes the reabsorption of sodium in 
exchange of potassium in the distal nephron.  Aldosterone provokes 
endothelial cell dysfunction, inhibition of NE uptake, baroreceptor 
dysfunction, any or all lead to worsening of HF. The action of aldosterone 
in the cardiovascular system  may be due to oxidative stress with resultant 
inflammation in target tissues, low dose spironolactone increased the 
survival of  patients with systolic heart failure and also improves the 
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survival after myocardial infarction , independent of changes in 
electrolyte status or volume 
 
OXIATIVE STRESS5,6 
 Oxidative stress in the heart may be due to the increased 
production of  ROS or reduced antioxidant capacity , which may arise 
secondary to neurohormonal stimulation (angiotensin II, alpha-adrenergic 
agonists, ET-1), mechanical strain of the myocardium,  or inflammatory 
cytokines (tumor necrosis factor, IL-1). 
 
NEUROHORMONAL ALTERATION OF RENAL FUNCTION7,8 
 Salt and water retention due to either “forward” failure, due to 
inadequate renal perfusion as a consequence of impaired cardiac output, 
or “backward” failure, in which  increased venous pressure in favoring 
transudation of salt and water from the intravascular to the extracellular 
compartment. 
 These mechanisms have largely been supplanted by the concept of 
decreased effective arterial blood volume, which postulates that despite 
blood volume expansion in HF, inadequate cardiac output sensed by 
baroreceptors in the vascular tree leads to a series of compensatory 
neurohormonal adaptations that resemble the homeostatic response to 
acute blood loss..  
14 
 
Increased renal sympathetic nerve activation leads to 
i. Vasconstriction leads to increased renal tubular water, sodium 
reabsorption throughout the nephron. 
ii. Nonosmotic release of arginine vasopressin (AVP)  
iii. Endothelin production 
 
ARGININE VASOPRESSIN  
(i) AVP is a pituitary hormone that plays a central role in the 
regulation of free water clearance and plasma osmolality 
(ii) AVP is released in response to an increase in plasma osmolality, 
leading to increased retention of water from the proximal duct.  
(iii) In heart failure it is nonosmotic release and contribute to the 
hyponatremia in HF. 
(iv) The cellular effects mediated mainly by three types of receptors, 
termed V1a, V1b, and V2. The V1a receptor is present primarily in 
vascular smooth muscle cells. The V1b mainly in the central 
nervous system. 
(v) The V2 receptors are found   in the epithelial cells in the renal 
collecting duct and the thick ascending limb. 
(vi) AVP receptors are members of the G protein–coupled receptors. 
(vii) The V1a receptor mediates vasoconstriction, platelet 
aggregation, and stimulation of myocardial growth factors;  
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(viii) the V1b receptor modulates adrenocorticotropic hormone 
secretion from the anterior pituitary; 
(ix) V2 receptor mediates antidiuretic effects by stimulating adenylyl 
cyclase to increase the rate of insertion of vesicles containing 
water channels into the apical membrane. 
(x) Preferential action of  antagonists  V2 receptor causes retention 
of sodium, increase in  plasma renin activity, and plasma AVP, 
in contrast that of  V1 results in the raised cardiac output. 
(xi) The vaptans, vasopressin receptor antagonists with V1a 
(relcovaptan) or V2 (tolvaptan, lixivaptan) selectivity or 
nonselective V1a/V2 activity (conivaptan), have been shown to 
reduce body weight and to reduce hyponatremia. 
 The thirst center is stimulated by Angiotensin II and provokes the 
release of AVP and aldosterone, which can both lead to further 
dysregulation of salt and water homeostasis. 
 
 
Natriuretic Peptides 9,10,11 
(i) The natriuretic peptide system consists of five structurally 
similar peptides, termed ANP, urodilantin (an isoform of ANP), 
BNP, C-type natriuretic peptide (CNP), and dendroaspis 
natriuretic peptide (DNP) 
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(ii) Released in response to increase in atrial or myocardial strech 
(iii)  ANP in response to raise in atrial pressure is released in short 
bursts 
(iv) BNP regulation is transcriptionaly  mediated  in response to 
chronic increases in atrial or ventricular pressure 
(v)  ANP and BNP are  secreted as prohormones cleaved by corin 
and furin to yield large inactive substrate like N-terminal 
fragments (NT-ANP or NT-BNP) and smaller biologically 
active peptides (ANP or BNP). 
(vi)  ANP has a  short half-life of approximately 3 minutes, BNP has 
a plasma half-life of  20 minutes.  
(vii) CNP, located  in the vasculature, is also released as a 
prohormone that is cleaved into a  inactive form (NT-CNP) and  
active form (CNP). 
(viii) 1.increases excretion of sodium and water 
2.inhibits the release of renin and aldosterone 
3.inhibits fibrosis and increasing lusitrophy 
(ix) Natriuretic peptides are degraded by neutral endopeptidase. 
Inhibition of NEP may further potentiate the renal actions of 
ANP and BNP 
(x) Candoxatrilat , an endopeptidase inhibitor parentral formulation 
leads to reduction of right and left ventricular preload and that is 
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associated with fall in serum norepinephrine level and decrease 
in serum vasopressin level. 
(xi) Vasopeptidase inhibitors, such as omapatrilat, that inhibit both 
neutral endopeptidase and ACE were developed with the intent 
of inhibiting the RAS while concurrently elevating natriuretic 
peptide levels. 
In advanced heart failure ANP and BNP effects blunted due to 
the low renal perfusion pressure ,molecular form of natriuretic 
peptide is altered, decreased natriuretic receptors. 
 
 
EVALUATION OF THE PATIENT WITH HEART FAILURE 
Clinical Classification 
1. Decompensated heart failure 
2. Acute hypertensive heart failure  
3. Cardiogenic Shock 
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Diagnostic Criteria for Heart Failure in Population-Based Studies 
 
 
 FRAMINGHAM CRITERIA 
MAJOR 
CRITERIA 
MINOR CRITERIA 
MAJOR OR MINOR 
CRITERIA 
   
 Paroxysmal 
nocturnal 
dyspnea or 
orthopnea 
   
 Neck-vein 
distention 
    Rales 
   
 Cardiomegaly 
   
 Acute 
pulmonary 
edema 
    S3 gallop 
   
 Increased 
venous 
pressure, 
>16 cm H2O 
   
 Hepatojugular 
reflux 
 
    Ankle edema 
    Night cough 
   
 Dyspnea on 
exertion 
    Hepatomegaly 
    Pleural effusion 
   
 Vital capacity 
decreased by 
one third from 
maximal 
capacity 
   
 Tachycardia 
(rate > 120 
beats /min) 
 
Weight loss > 4.5 kg 
in 5 days in response 
to treatment 
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OTHER CRITERIA FOR THE DIAGNOSIS OF HEART FAILURE 
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DIAGNOSTIC TESTING 
Measurement of Blood Chemistry and Hematologic Variables  
 Blood chemistries and hematologic variables are routinely 
measured as part of the initial heart failure evaluation. Hyponatremia is 
the most common electrolyte abnormality in heart failure patients, 
particularly during periods of decompensation. Although hyponatremia is 
associated with significantly higher in-hospital and follow-up mortality 
and longer hospital stays. Hyponatremia, however, has been associated 
with impaired cognitive and neuromuscular function. Besides increasing 
the risk of cardiac arrhythmias, it can cause further muscle weakness. 
Additional electrolyte abnormalities include hypomagnesemia and 
hypophosphatemia. 
 Renal function should be measured as part of the initial evaluation. 
Dronedarone, an agent used to treat intermittent or recurrent atrial 
fibrillation, can also increase creatinine levels. [14] Impaired renal function 
at baseline and worsening during hospitalization are both potent 
predictors of poor outcome. 
 Diabetes is common in heart failure patients. Because diuretics can 
cause gout, measurement of uric acid levels can help in management of 
the patient. Abnormalities in aspartate aminotransferase and alanine 
aminotransferase may occur in heart failure patients as a consequence of 
either hemodynamic derangements or medications, and it is important to 
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follow levels periodically. An unexpected increase in prothrombin time in 
patients receiving warfarin therapy may be an early harbinger of 
decompensation as it may reflect impaired synthetic capacity of a 
congested liver. Albumin levels are an indication of the patient's 
nutritional status, and they may be depressed because of poor appetite or 
impaired absorption across an engorged bowel wall. Elevations in 
bilirubin are most often seen during episodes of severe decompensation. 
 Low hemoglobin levels have been associated with more severe 
symptoms, reduced exercise capacity and quality of life, and increased 
mortality[15,16] . Although anemia may be a consequence of chronic 
disease in heart failure patients, a low hemoglobin level should trigger an 
evaluation to detect treatable causes. The leucocyte count and differential 
are helpful in detecting the presence of infection that is responsible for 
destabilizing a previously well-compensated patient and could provide a 
clue that heart failure is due. A BNP level above 400 pg/mL in this 
setting make the diagnosis of heart failure likely. A level of NT-proBNP 
of 300 pg/mL has been set as a cut off for excluding or including the 
diagnosis of heart failure 
Chest Radiography  
 It is taken to rule out other causes of dyspnoea. A “butterfly” 
pattern of alveolar opacities that fan out bilaterally from engorged hilar 
pulmonary arteries to the periphery of the lungs is the classic pattern of 
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congestion seen in decompensated heart failure . Pleural effusions or fluid 
in the right minor fissure may also be seen. The chest radiograph may 
also provide an indication that heart failure is due to coronary, valvular, 
or pericardial disease when calcification is noted in the appropriate 
position. 
 
Electrocardiography  
 Sinus tachycardia secondary to sympathetic nervous system 
activation is seen with advanced HF or during episodes of acute 
decompensation. Atrial arrhythmia on the ECG, as well as the ventricular 
response, may provide clues to the cause of HF and gives the reason for 
decompensation. Increased QRS voltage may suggest left ventricular 
hypertrophy, if right ventricular hypertrophy is present primary or 
secondary pulmonary hypertension should be considered. Low QRS 
voltage suggests the presence of an infiltrative disease or pericardial 
effusion. The presence of Q waves suggests that HF may be due to 
ischemic heart disease; new or reversible ST changes identify acute 
coronary ischemia, which may be present even when chest pain is absent. 
acute coronary ischemia is a leading cause of acutely decompensated HF  
Prolongation of the PR interval is common in patients in this setting and 
may be due to intrinsic conduction disease but also may be seen in 
patients with infiltrative cardiomyopathy. With the advent of cardiac 
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resynchronization therapy, evaluation of the QRS complex has become a 
critical part of the clinical assessment in that it provides important 
information regarding the causes of HF, as well as providing pivotal 
information regarding the therapeutic approach. The QT interval often is 
prolonged in patients with HF, which may be due to electrolyte 
abnormalities, myocardial disease, or effects of commonly used drugs, 
such as antiarrhythmics. 
 
Echocardiogram 
 Transthoracic echocardiography is an important part of the 
evaluation of HF. It is particularly well suited for evaluating the structure 
and function of both the myocardium and heart valves and providing 
information about intracardiac pressures and flows. For patients with 
HFpEF, left ventricular volumes and systolic function can be assessed 
semiquantitatively, or quantified using the biplane method and the 
modified Simpson’s rule. Diastolic function is assessed using Doppler 
measurements, including analyses of the mitral valve inflow pattern 
(early [E] and atrial [A] waveforms), tissue velocities at the mitral valve 
annulus, pulmonary vein flow, and the left atrial volume indexed to body 
surface area. Diastolic dysfunction can be further classified as grades I to 
III based on the foregoing measurements, with incremental prognostic 
importance in HF as worsening grades of diastolic dysfunction are noted. 
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Pulmonary hypertension in patients without significant systolic 
dysfunction or pulmonary disease suggests that diastolic dysfunction may 
be present. 
 Another advantage of echocardiography is the ability to noninva-
sively estimate right-sided heart pressures. For example, right atrial 
pressures are estimated by the inferior vena cava (IVC) diameter and the 
relative change in diameter on inspiration. Normal IVC diameter and 
inspiratory collapse of at least 50% are associated with normal right atrial 
pressures, whereas increased IVC diameter and smaller inspiratory 
changes indicate elevated right atrial pressure MRI and CADIAC CT can 
also be done, MRI predicts morphology, function, tissue metabolism but 
CT can do evaluate only morphology and function  
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TREATMENT OF HEART FAILURE  
NON –PHARMACOLOGICAL THERAPIES 
DIET 
1. Dietary restriction of sodium 2-3 gram daily is recommended for 
all patients, regardless of left ventricular ejection fraction.  
2. Fluid restriction less than 2 litre daily if serum sodium less than  
130mEq /L  
3. Prealbumin and caloric evaluation 
OTHER THERAPIES 
1. Continuous positive airway pressure if diagnosis of sleep 
apnoea is present, symptoms of dyspnoea improves 
2. Oxygen supplementation 
3. Depression if present treated with appropriate therapy 
 
ROUTINE HEALTHCARE 
1. Avoidance of alcohol less than 2 drink in male and 1 drink in 
female. In alcoholic cardiomyopathy, total abstinence is 
recommended 
2. Vaccinations like pneumococcal and influenza is recommended 
3. Exercise training , moderate exercise activity for 30 minutes at 
least 5 days per week 
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PHARMACOLOGICAL THERAPIES 
It is based on the stages of heart failure 
STAGES OF HF23 
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AHA guideline for treatment of heart failure 
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Goal of treatment  for each stages of heart failure 
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LOOP DIURETICS 19,20 
 
 Furosemide, bumetanide, and torsemide, are the loop diuretics act 
by reversibly inhibiting the Na+-K+-2Cl− symporter.  
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Mechanisms of Action 
 By inhibiting the concentration of solute within the medullary 
interstitium, these drugs also reduce the driving force for water resorption 
in the collecting duct, even in the presence of AVP.  Furosemide acts as a 
venodilator and reduces right atrial and pulmonary capillary wedge 
pressure within minutes when given intravenously (0.5 to 1.0 mg/kg).  
 
Thiazide and Thiazide-Like Diuretics  
 The benzothiadiazides, also known as thiazide diuretics, were the 
initial class of drugs synthesized to block the Na+-Cl− transporter in the 
distal nephron. As a result of  its action the sodium delivery is increased 
in the collecting tubules and that leads to enhanced sodium reabsorption 
in this segment in exchange of H+ and K+  ions that leads to hypokalemia 
 
Mechanisms of Action  
 The efficacy of thiazide diuretics is dependent, at least in part, on 
proximal tubular secretion to deliver these agents to their site of action.. 
 
Mineralocorticoid Receptor Antagonists  
 These agents are used in patients more for their ability to 
antagonize the renin angiotensin aldosterone system  than for their 
diuretic properties.  
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Potassium-Sparing Diuretics  
 Triamterene and amiloride are referred to as potassium-sparing 
diuretics. Its action is carried out by the blockade of epithelial sodium 
channel present in the principal cells of late distal tubule and collecting 
duct 
 
Carbonic Anhydrase Inhibitors  
 The use of these agents in patients with HF is restricted only in 
occasions of  metabolic alkalosis that occurs at times of ECF contraction 
in diuretic  usage. 
 Diuretics started at lower level and dose is increased until patient 
attains the euvolemic state.  . Intravenous administration of loop diuretics 
helps to decrease the symptoms of acute heart failure symptoms briefly. 
On attaining the steady state of  euvolemia , small doses of diuretics are 
given repeatedly like thrice a day orally, than a single large dose  
 
Complications of Diuretic Use  
Electrolyte and Metabolic Disturbances  
 It can lead to potassium depletion, which can predispose the patient 
to significant cardiac arrhythmia.  
 The serum potassium should be within the range of 4 to 5 
milliequivalent/L   
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 Hyponatremia 
 Hypomagnesemia 
 Metabolic alkalosis 
 Hhyperglycemia 
 Hhyperlipidemia 
 Hhyperuricemia 
 Potassium chloride supplementation or acetazolamide used to 
relieve metabolic alkalosis 
 
 Hypotension and Azotemia  
 Neurohormonal Activation  
 Ototoxicity, which is more frequent with ethacrynic acid than the 
other loop diuretics, reversible. Ototoxicity occurs most frequently 
with rapid intravenous injections, and least frequently with oral 
administration. 
 Diuretic Resistance.  
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Drugs for the Prevention and Treatment of Chronic Heart 
Failure13,14 
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N-3 Polyunsaturated (Omega-3) Fatty Acids  
 These drugs have favorable effects on inflammation, including a 
reduction of endothelial activation and production of inflammatory 
cytokines, platelet aggregation, autonomic tone, blood pressure, heart 
rate, and LV function  
 
Ivabradine  
 Ivabradine acts by decreasing the heart rate. If(“funny”) current is 
blocked by this agent that decreases the rate of depolarization  during the 
diastole. It acts mainly in sinoatrial node. So this drug used in  patients in 
sinus rhythm.  
 It acts from the intracellular site, so it can block the channel while 
it is open.  It is more effective while treating a patient in the fast heart 
rate, as it’s action depends on the frequency of opening of the If channel 
 Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial 
(SHIFT), in this study patients with severe left ventricular dysfunction 
proved on echocardiogram is enrolled, the heart rate cut off is 70 beats 
per minute and above , the dose of the drug is 7.5 mg twice a day.  There 
was a decrease in the hospitalization of about 18% and mortality is also 
decreased. 
 BEAUTIFUL trial more than 10000 patients were enrolled, in that 
patient ejection fraction is fixed at 40% or less and the underlying causes 
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were post myocardial infarction, hypertensive heart disease, etc. this trial 
showed that the patient tolerated this drug better as the side effects were 
low. 
  
Cardiac Glycosides 
 Digoxin and digitoxin are more commonly used drug in severe LV 
dysfunction. Digoxin acts by inhibiting the Na+-K+ATPase(sodium 
potassium adenosine trisphosphate). This leads to an increase in 
intracellular calcium and hence increased cardiac contractility, because of 
its ionotropic property. 
In the heart failure it acts also by improving the vagal sensitization and 
therefore counterbalancing the effect of sympathetic overactivity.  Its 
action on renal tubules by  blunting  the absorption of sodium as the 
channel is same as that of myocardium. 
 
 Dose is started with 0.125 to 0.25 mg daily and the serum digoxin 
level should be below 1.0 ng/mL in 
 1. Low BMI patients 
 2. Old age 
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Complications of Digoxin Use 
 Adverse effects of digoxin are 
(i) Cardiac arrhythmias including heart block (especially in the 
elderly) and ectopic and reentrant cardiac rhythms 
(ii) Neurologic complaints such as visual disturbances, disorientation,    
and confusion; 
(iii) Gastrointestinal symptoms such as anorexia, nausea, and vomiting 
serum K+  are monitored, The concomitant use of quinidine, 
verapamil, spironolactone, flecainide, propafenone, and 
amiodarone  increases the drug level so frequent monitoring to be 
done.  
  
37 
 
Drug that affects the serum level of digoxin 
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Renin Inhibitors  
 Aliskiren is the drug  in this group which is orally active and it 
directly inhibits the renin.  
 Its action similar to that of the ACE inhibitors. ACE inhibitor use 
leads to raise in renin level in the plasma. This raised renin level can 
activate renin angiotensin system and decrease the effect of ACE 
inhibitor. Renin inhibitors used in these situation 
 
Management of Atherosclerotic Disease  
 Aspirin can be added to prevent any complications of 
atherosclerosis, studies shown its relevance but not yet proven in heart 
failure. 
Anticoagulation and Antiplatelet Therapy 15 
Treatment with these drugs are recommended in 
1. arrhythmias 
2. anterior wall myocardial infarction 
3. myocardial infarction with clot noted in echocardiogram 
4. history of systemic embolization like transient ischemic attack or 
pulmonary embolism 
 treatment continued for three months unless it is contraindicated  
 INR maintained at 2 to 3 
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Treatment of Cardiac Arrhythmias  
1. atrial fibrillation occurs in 15% to 30% of patients with HF, and is 
a frequent cause of cardiac decompensation  
2. only amiodarone and dofetilide are used as only these drugs does 
not have negative ionotropism and does not provoke arrhythmia.  
3. Drug interactions of amiodarone is high, as it interacts with many 
drugs that used in heart failure like warfarin and digoxin 
4. Dose of amiodarone is decreased to50% in these patients, to avoid 
drug interactions. As other side effects of amiodarone like 
hyperthyroidism,hepatitis, pulmonary fibrosis is low in this low 
dosage about 100 to 200mg per day 
5.  Dronedarone is a novel antiarrhythmic drug that reduces the 
incidence of atrial fibrillation and atrial flutter and has 
electrophysiologic effects similar to those of amiodarone but side 
effects are less than amiodarone due to absence of iodine moiety. 
Device Therapy16  
 Device therapy can improve the quality of life in patients with 
sinus rhythm. There is decrease in probability of hospitalization in those 
patients with device therapy 
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SURGICAL MANAGEMENT 
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MANAGEMENT OF CSA IN HEART FAILURE17 
 HF patients with a reduced EF (<40%) commonly exhibit sleep-
disordered breathing; approximately 40% of patients exhibit central sleep 
apnea (CSA), commonly referred to as Cheyne-Stokes breathing  whereas 
another 10% exhibit obstructive sleep apnea (OSA) 
 Risk factors for the development of CSA in HF patients include 
male gender, age older than 60 years, presence of atrial fibrillation, and 
hypocapnia. The main clinical significance of CSA in HF is its 
association with increased mortality.  
 The potential mechanism(s) for adverse outcomes in HF patients 
with CSA may be attributed to marked neurohumoral activation, 
especially norepinephrine.   
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 Continuous positive airway pressure (CPAP) breathing has been 
shown to improve LV structure and function in patients with OSA or 
CSA disturbed breathing syndrome. 
Disease Management  
 Technology-driven strategies that use low-cost telemonitoring also 
appear promising in terms of improving HF management and outcomes, 
emphasizing the importance of team management in the care of these 
complex patients18. Ideal guideline recommended treatment group in a 
study showed decrease in rehospitalization. 
Patients with Refractory End-Stage Heart Failure (Stage D)  
 Those patients in this stage is referred for advanced treatment like 
mechanical circulatory support, continuous intravenous positive inotropic 
therapy, Cardiac transplantation. 
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PHASES OF MANAGEMENT 21,22 
 
PHASE I EMERGENT CARE      
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Phase II: Hospital Care 
 The main aspect of treatment at the time of hospital admission is 
the completion of diagnostic workup and the emergent therapeutic 
process that was started at the time of admission for pulmonary edema 
and to correct the hemodynamic derangements. The goal is to attain a 
state of optimal treatment that correct the volume status, symptoms and 
plan the therapy of chronic heart failure 
 These are optimized to decrease the duration of stay in the hospital, 
and intensive care. Surveillance of day to day weight of the patient, input 
output chart of the patient,orthostatic fall in blood pressure , signs and 
symptoms of congestion is important during this phase.  Echocardiogram 
and electrocardiogram is done to evaluate the cause of decompensation, 
as myocardial infarction is frequently associated.  
 Restriction of sodium less than two gram per day and amount of 
water or other fluid to less than two litre per day is instituted.  
 As there is risk of systemic and pulmonary embolization in these 
patients, to start on warfarin or heparin is indicated unless it is 
contraindicated as the patient is mostly bed ridden  
 During hospitalization itself the patient is started on the drugs that 
is prescribed during the discharge and the most important aspect is to 
include angiotensin converting enzyme inhibitor and aldosterone 
antagonist unless the patient urea and creatinine shows a raising trend. 
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 Those who were started on betablocker in a trial showed decreased 
incidence of ventricular tachycardia, decreased length of hospital stay, 
decreased mortality compared to the control who were not on the 
betablocker. 
 Beta blocker therapy is given unless the patients in cardiogenic 
shock or persistent hypoperfusion . ACE inhibitors, angiotensin receptor 
blockers, mineralocorticoid receptor antagonists, and isosorbide 
dinitrate/hydralazine should be continued unless there is situations of 
withdrawal. 
 During this phase patient is taught about the importance of the 
treatment schedule and the self care Programme arranged to learn about 
the specific drugs and importance of daily weight measurement and the 
awareness about the heart failure and behavior therapy is also instituted. 
self-adjustment of diuretics, exercise programs, and nutritional 
counseling are also done.  Comorbid conditions also given importance to 
these patients, and advice about its management and care is given.  
 
  
46 
 
The Cardiorenal Syndrome in Hospitalized Patients  
 It is diagnosed, in the presence of the systemic congestion if the 
patient shows raise in creatinine 0.3 mg/dL or if there is fall in glomerular 
filtration rate about 25% from the base line. 
 It is associated with the increase in duration of the stay and 
postdischarge mortality and morbidity, therefore readmissions 
Angiotensin converting enzyme inhibitor and aldosterone antagonist are 
to be discontinued in the presence of increasing trend of creatinine value 
(BUN value more than 80 mg/dL and creatinine above 3 mg/d).. 
 In these situations vasodilator therapy like (nitroglycerin or 
nitroprusside) and (hydralizine or isosorbide dinitrate) is used to relieve 
the congestion. 
 These situations leads to a state of diuretic resistance, so there is a 
need of raising dose of diuretics. Ultrafiltration can be used to relieve the 
symptoms but vasodilators is superior as they preserve the renal function. 
 
Phase III: Predischarge Planning  
 It is based mainly on giving the optimial therapy to each patient, 
patient must be stabilized on the chronic outpatient therapy and the side 
effects of the drugs must be minimized by prescribing dosage that are 
appropriate  
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Criteria for discharging the patient 
 
Phase IV: Postdischarge Management  
After the discharge patient must be advised to attend the follow up 
care within 7 to 10 days. This can be adjusted as earlier as possible in 
patients with high risk. As the neuohormonal activation due to congestion 
is the most common reason for recurrence of the symptoms. 
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 The Rehospitalization Problem 
  In the EVEREST study, followed up the patients with 
readmissions, showed that 46% were for heart failure, 15% for other 
cardiovascular causes, and 39% were for noncardiovascular causes. 
Hospitalizations in heart failure are the major burden in all over the 
world.  
 Use of appropriate drugs and dosage that reduce hospitalization are 
ACE inhibitors and beta blockers that are proven in many studies. 
 
Potential Precipitating Factors of Acute Decompensation in Patients 
with Chronic Heart Failure 
    Dietary indiscretion 
    Inappropriate reduction in HF medications 
    Myocardial ischemia, infarction 
    Arrhythmias (tachycardia, bradycardia) 
    Infection 
    Anemia 
   
 Initiation of medications that worsen the symptoms of HF  
    Calcium antagonists (verapamil, diltiazem) 
    Beta blockers 
     Nonsteroidal anti
    Thiazolidinediones
    Antiarrhythmic agents (all Class I agents, sotalol [Class 
    Anti-TNF antibodies
 
    Alcohol consumption
    Pregnancy 
    Worsening hypertension
    Acute valvular insufficiency
 
 
OVERVIEW OF TREATMENT OPTIONS IN HEART FAILURE 
PATIENTS 
49 
-inflammatory drugs 
 
 
 
 
 
III]) 
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FACTORS THAT ARE CONSIDERED AS PROGNOSTIC 
MARKERS ARE ILLUSTRATED 
 HOSPITALIZATION24 
 Poor prognostic factor is need for hospitalization. Mortality rate is 
high after hospitalization, more within one month of discharge. 
Contributing factor is poor compliance in many patients who is requiring 
readmissions. 
 
SURVIVAL IN HEART FAILURE25 
DURING HOPITALIZATION 
 Mortality is high if in-hospital stay is decreased. The decrease in 
duration of hospital stay is associated with increase in post discharge 
mortality, as the patients are discharged in unstable conditions and 
thereby readmission rate is increased 
 
LONG TERM MORTALITY26,27,28 
 It is studied in various studies and it states  that it is declining. In a 
study of patients with systolic dysfunction on angiotensin converting 
enzyme inhibitor along with some taking spironolactone , cardiovascular 
death incidence or symotomatic failure was 39 % over 3 years. 
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PREDICTIVE MODELS29 
Variety of predictors has been identified 
 
HEART FAILURE SURVIVAL SCORE30  is based on 
1. Ejection fraction  
2. Peak o2 
3. Serum sodium 
4. Mean blood pressure 
5. Resting heart rate 
6. Coronary vascular disease 
7. ECG showing intraventricular conduction delay 
 
 SEATLE HEART FAILURE MODEL is a multivariable analysis 
model using demographic and clinical markers to predict the survival. 
 
Effect of age - Increasing age has impact over mortality and morbidity31 
Effect of gender32 
     Women having better prognosis than men, in PRAISE, PRAISE II, 
MERIT HF, VEST, PROMISE trial proposed this. 
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CAUSE OF CARDIOMYOPATHY33 
 Peripartum cardiomyopathy has better prognosis.  Infiltrative, HIV, 
DOXORUBICIN therapy, ischemic heart disease, connective tissue 
disease has worse prognosis.  
 But prognosis is same in hypertension, substance abuse, 
myocarditis. 
 SOLVD treatment trial showed diabetes increases the mortality in 
all cause HF. 
 
SEASONAL VARIATION34,35 
 Winter spring predominance in hospitalization, fatal events are 
more common in winter in a large study from france 
 
CIRCARDIAN RHYTHM36 
 There is a PM peak of SCD  in ischemic cardiomyopathy, PRAISE 
trial also found that  there is a uniformity in sudden cardiac death in non 
ischemic and that PM peak of ischemic cardiomyopathy mortality  is not 
altered by antiischemic and antithrombotic therapy.  
 
DIASTOLIC DYSFUNCTION 
 The prognosis less defined in studies, some shows mixed results 
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EFFECT OF TREATMENT 
 SOLVD trial  of NYHA classII and III, showed decrease in four 
year mortality rate with the use of enalapril  from 42 to 36% 
 In MERIT-HF trial use of ACE inhibitor , digoxin in NYHA class 
II and III  patients addition of metoprolol have a significant reduction in 
one year mortality. 
 
PROCESS OF CARE MEASURES  
 Improved outcomes in outpatient process-of-care measures, as 
observed by an observational study of 15,177 patients with left 
ventricular ejection fraction ≤35 percent and chronic heart failure or post-
myocardial infarction. Two-year survival was improved with process 
measures including adherence to evidence-based drug and device 
therapies. 
 
CAUSE OF DEATH IN HEART FAILURE37,38,39 
1. Sudden cardiac death 
2. Progressive heart failure 
 Sudden death, progressive pump failure, sudden death during 
worsening account for approximately one-third of death.  
 Ventricular tachycardia converting to ventricular fibrillation 
common cause of death.  
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 Angiotensin converting enzyme, beta blocker, aldosterone 
antagonists improve the survival.  ICD arm showed promising decreasing 
mortality.  
 
ROLE OF ISCHEMIA40 
 It is underestimated in sudden cardiac death.  
 
NYHA functional class   
 
 
 
 
 
 
 
 
With 6 and 12 month mortality rates of 44 and 64 % in patients 
with NYHA class IV. 
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Left ventricular ejection fraction   
 Symptoms of systolic heart failure starts when ejection fraction 
declines below 35 to 40%. Symptoms does not depend on ejection 
fraction. Very low ejection fraction like 20% may be asymptomatic 
As an univariate predictorof prognosis is not useful, if used with NYHA 
class it is best predictor of prognosis.  
 
Concomitant diastolic dysfunction  
 Mitral flow velocity is used to detect diastolic dysfunction 
Difference in changes during nitroprusside infusion like 
 Irreversible restrictive, unstable restrictive, reversible restrictive, 
stable restrictive patterns are observed. 
 Each having 51%, 33%,19%, 6% cardiac event rate 
 Effect of dobutamine is observed 
 Restrictive pattern causes elevation of left atrial pressure and 
decrease in response to ionotropins 
 
Right ventricular function  
 Independent risk in survival of patients in heart failure is Right 
ventricular systolic dysfunction 
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Pulmonary artery pressure   
 Each 5 mmHg raise in mean pulmonary artery pressure from base 
line, the mortality with and without myocarditis is increased. 
 
Other echocardiographic findings  
 Others include 
• LV end-diastolic volume index >120 mL/m2  /LV dilatation  
• LV systolic diameter index >2.75 cm/m2 and restrictive 
mitral filling pattern 
• Increased LV mass  
• Increased left atrial size  
 
QRS prolongation and LBBB   
1. qrs duration >120ms 
2. Left bundle branch  predicts poor outcome 
 
Exercise variables   
 Peak VO2, six-minute walk distance, and exercise hemodynamics 
have been correlated with patient survival. 
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Signs of reduced tissue perfusion    
 A low mean arterial blood pressure, renal insufficiency, an 
attenuated response to diuretics, and lack of hemodynamic improvement 
with therapy, as indicated by failure to reduce LV filling pressure, are 
also associated with a poorer prognosis  
 
Reduced myocardial blood flow   
 In patients with idiopathic cardiomyopathy, reduced myocardial 
blood flow, as assessed by positron emission tomography at rest and after 
intravenous dipyridamole , is an independent predictor of subsequent 
cardiac event.  
 
Atrial fibrillation   
 Prevalence is high and dilemma weather it is an independent factor 
or associated with worsening of heart failure  
 
Physical findings 
S3 gallop and jugular venous pressure   
 Its presence has a prognostic significance. 
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Functional MR   
 Functional mitral regurgitation may be moderate to severe and is 
associated with poor prognosis  
 
C-reactive protein  is a survival guide in ischemic cardiomyopathy 
 
Heart rate variability   
 Reduced heart rate variability indicates increased sympathetic or 
reduced parasympathetic tone has poor prognosis 
Planar QRS-T angle   
 Nonsustained VT or frequent ventricular ectopy, a planar QRS-T 
angle more  than 90 degrees was a predictor of the composite end point of 
total mortality 
 
Troponins   
 High troponin T (TnT) and troponin I (TnI) have a poor prognosis  
 
Low serum cholesterol   
 Possibly due to statin therapy 
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Hyperuricemia    
 May be due to diuretic therapy or due to low cardiac output state 
 Studies shown that allopurinol improves endothelial function and blood 
flow. 
 It is also proved as a risk factor for coronary artery disease 
 
Weight loss and BMI   
 Patients with BMI <30 kg/m2 higher mortality than with BMI  
within 30 and 34.9 kg/m2 
 High plasma adiponectin indicates wasting so correlated with poor 
prognosis. 
 Although obesity associated with coronary heart disease but it does 
not correlate with mortality in heart failure 
 
Hypoalbuminemia and liver function abnormalities   
 Hypoabubimemia depends on 
   nutritional status, 
   hepatic function, 
   hemodilution, 
   inflammatory state 
60 
 
elevated alkaline phosphatase, elevated alanine aminotransferase elevated 
aspartate aminotransferase  are seen in an multivariate analysis total 
bilirubin is a better tool for prognosis in heart failure  
 
Anabolic hormones   
 Decreased anabolic steroid and isulin like growth factor is 
associated with poor prognosis in men 
 
Albuminuria   
 It has poor prognostic marker it is associated more often with class 
III and IV heart failure 
 
Depression   
 Depression appears to be both relatively common and associated 
with a worse prognosis in patients with heart failure 
 
mIBG imaging   
 Metaiodobenzylguanidine (mIBG) is an analog of norepinephrine 
(NE) that is taken up into cardiac sympathetic nerve endings in the same 
manner as NE. This uptake is decreased in HF. Radionuclide scintigraphy 
using I-123-mIBG correlates with established indices of HF severity, 
including LVEF, CI, PCWP and peak VO2  
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COMORBIDITIES 
ANEMIA41 
Etiology:  
1. Increased cytokines in circulation 
2. Dilutional anemia42 
3. Iron deficiency43,44 
4. Use of angiotensin converting enzyme inhibitor45 
5. Cardiorenal syndrome46,47,48 
Development of high output heart failure 
Hemoglobin less than 5g/L produces failure in the absence of 
underlying heart failure 
One study showed , each 1gm/dL decrease has independent 
association with left ventricular dilation.  
 
IMPACT OF ANEMIA ON MORTALITY50 
1. Worse hemodynamics49, high urea nitrogen in blood, low 
albumin 
2. Greater NYHA classIV occurrence  
3. Low peak oxygen consumption 
It is an independent risk factor for mortality in heart failure patients 
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IMPACT OF POLYCYTHEMIA51 
 It is also increase the mortality, correlate to presence of COPD 
 
TREATMENT OF ANEMIA52,53 
 Intravenous iron can be used and provide symptomatic relief in 
hemoglobin below 13 gm/dl and low ferritin(<100microgram/L ) and 
transferrin saturation(<20%) 
 
DIABETES AND HF54 
 Framingham study showed a epidemiological link between 
diabetes and heart failure 
Factors associated are55-57,58,59  
1. Age 
2. Duration of DM 
3. Insulin use 
4. Ischemic heart disease 
5. PVD(peripheral vascular disease) 
6. Raised serum creatinine 
7. Poor glycemic control 
8. Microalbuminuria 
9. increase in baseline fasting plasma glucose associated with 
increase risk of  HF 
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10. thiozolindinediones and metformin have  toxicities that worsens 
HF 
11. diabtetes perse causes diastolic and systolic dysfunction leads to 
diabeteic cardiomyopathy 
12. AHA guideline suggests avoidance of  thiozolindinediones and 
metformin inNYHA class III and IV dyspnoea60-66 
 
PREDICTORSOF HOSPITAL READMISSION WITH HEART 
FAILURE 
 Heart failure has emerging as the leading cause of hospitalization.  
Ischemic etiology is known cause of mortality and readmission in heart 
failure patients. Powerful predictor of prognosis is left ventricular 
function,  
 Krumoltz et all examined readmission in patients with heart failure, 
he found four major predictors  
1. Prior history of hospitalization within one year 
2. Prior heart failure history 
3. Elevated renal parameters >2.5  during prior discharge 
4. Co-morbid illness like diabetes mellitus 
Other studies showed the predictors of  outcome during admission are  
1. Hemodynamic abnormalities 
2. Plasma atrial natriuretic peptide 
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3. Inotropic reserve 
4. Plasma epinephrine 
5. Total oxygen consumption during peak exercise 
  
 LACE INDEX SCORE OF READMISSIONS
 
 SCORE of 10 or more is used to segregate the patients with high 
risks 
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MATERIALS AND METHODS 
  
66 
 
MATERIALS AND METHODS 
SELECTION OF PATIENTS: 
Patients admitted for heart failure previously in madras medical 
college and Rajiv Gandhi government general hospital and now 
readmitted with history of heart failure symptoms are included in the 
study. On admission 10cc blood is withdrawn from the patient after 
obtaining the informed consent either from the patient or the relatives. 
The sample is tested for complete blood count, renal function tests, liver 
function tests and serum electrolytes. As this study is both prospective 
and retrospective the lab parameters and clinical parameters of patients 
previously admitted are obtained from medical records department, Rajiv 
Gandhi government general hospital. 
 
STUDY CENTRE: 
Institute of Internal Medicine,  
Madras Medical College and Rajiv Gandhi Government General 
Hospital, Park town, Chennai-600003. 
 
DURATION OF THE STUDY: 
6  months(April 2014 – September 2014) 
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STUDY DESIGN: 
Prospective and Retrospective observational study 
 
SAMPLE SIZE: 
98  PATIENTS 
 
DATA COLLECTION AND METHODS: 
 Patients are subjected to history questioning, clinical examinations 
and blood sampling. Retrospective samples are obtained from case sheet 
records at medical records department. 
 
PROCEDURE / INVESTIGATION DETAILS: 
1. Complete Blood Count 
2. Renal Function Test – Urea, Creatinine 
3. Serum Sodium 
4. Serum Potassium 
5. ECG 
6. Echocardiogram 
7. Chest X Ray 
8. Pulse Rate 
9. Blood Pressure. 
  
68 
 
INCLUSION CRITERIA : 
1. Age: above 15 years. 
2. Sex-both genders. 
3. Patients presenting with symptoms of heart failure according to 
Framingham criteria. 
4. Patients willing to give written informed consent. 
 
EXCLUSION CRITERIA : 
1. Patient age less than 15 years 
2. Patient who was previously admitted for symptoms of heart failure 
and now admitted for another cause 
 
SPONSORSHIP :   
 NO 
 
CONFLICT OF INTEREST : 
None 
  
  
 
 
 
OBSERVATION 
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OBSERVATION AND RESULTS 
Table 1: Showing age wise distribution of study population 
 
Age Patients Percentage 
15-29 4 4% 
30-44 19 19.3% 
45-55 44 44.8% 
>55 31 31.6% 
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Table 2: showing age wise distribution of study population 
  
Sex No of Patients Percentage 
Male 58 59.1% 
Female 40 40.9% 
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Table 3: Showing bilirubin elevation in study population  
 
   
Total Billirubin No of Patients Percentage 
Elevated 6 6.1% 
Not Elevated 92 93.9% 
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Table 4: Showing duration of stay in the study population 
 
  
Days No. of Patients Percentage 
1-4 DAYS 31 31.63% 
5-9 DAYS 45 45.91% 
>10 DAYS 22 22.40% 
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Figure 4: showing duration of stay in the study population  
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Table 5 : Showing Underlying Cause for heart failure in study 
population 
 
 
UDERLYING CAUSES 
Hypertensive heart disease-1 
Ischemic heart disease-2 
Other cardiomyopathies-3 
Valvular heart disease-4 
Atrial fibrillation or flutter-5 
Underlying Cause No of patients Percentage 
1 8 8% 
2 35 35.70% 
3 11 11.20% 
4 11 11.20% 
1,2 17 17.30% 
1,3 1 1% 
1,4 1 1% 
2,4 3 3% 
4,5 11 11.20% 
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Figure  5  : Showing Underlying Cause for heart failure in study 
population 
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Table 6 : Showing comorbid illness in study population 
 
 
1- Acute or chronic renal disease 
2-Chronic lung disease 
3-Diabetes mellitus 
4-Anemia 
5-Drug or alcohol abuse 
  
Comorbid illness No of patients Percentage 
1 7 7.10% 
2 3 3% 
3 26 26.50% 
4 13 13.20% 
5 6 6.10% 
1,2 1 1% 
1,3 3 3% 
1,4,5 1 1% 
1,5 1 1% 
3,4 1 1% 
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Figure  6 :  Showing comorbid illness in study population
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Table  7  : Showing precipitating Factor in study population  
Precipitating Factor No of patients percentage 
1 15 15.30% 
3 5 5.10% 
4 2 2% 
5 1 1% 
6 2 2% 
7 12 12.20% 
8 5 5.10% 
1,2 2 2% 
1,6 1 1% 
1,7 5 5.10% 
1,7,8 1 1% 
1,8  2 2% 
3,6 1 1% 
4,7 1 1% 
5,7 2 2% 
 
1-lack of compliance 
2-uncontrolled hypertention 
3-cardiac arrhythmias 
4-Inadequate therapy 
5-pulmonary infection 
6-emotional stress 
7-inappropriate medication or fluid overload 
8-myocardial infarction 
9-endocrine disorders  
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Figure 7  : Showing precipitating Factor in study population  
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Table 8 : Showing CXR findings in study population  
 
CHEST X RAY No of Patients Percentage 
Pulmonary hypertension grade I according 
to larry Elliot’s classification upper lobe 
veins prominent 
36 36.70% 
Grade II PHT either kerley A,B,C lines or 
hilar haziness 14 14.20% 
GradeIII PHT- bilateral patchy opacities 12 12.20% 
Pleural effusion 2 2% 
Postcapillary pulmonary arterial 
hypertension showing main pulmonary 
artery dilation 
22 22.40% 
Precapillary pulmonary arterial hypertension 2 2% 
Normal lung field 9 9.10% 
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Figure 8 : Showing CXR findings in study population 
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Table  9 : Showing RS examination in study population  
 
  
RS examination No of patients Percentage 
1 72 73.40% 
2 1 1% 
1,2 5 5.10% 
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Figure 9  : Showing RS examination in study population  
 
 
1. Basal crepitations 
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Table  10  : Showing CVS findings in study population  
 
CVS findings No of patients Percentage 
S3 heard 28 28.50% 
Systolic murmur heard 8 8.10% 
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Figure 10 : Showing CVS findings in study population 
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Table 11 : Showing echo findings in study population 
ECHO findings No of Patients Percentage 
3 2 2% 
4 12 12.20% 
5 8 8.10% 
6 6 6.10% 
7 7 7.10% 
8 8 8.10% 
1,3 10 10.20% 
1,4 3 3% 
1,6 1 1% 
1,7,9 1 1% 
1,8 1 1% 
2,3 1 1% 
3,7 1 1% 
4,5 1 1% 
4,8 4 4% 
5,10 1 1% 
5,4 1 1% 
5,8 4 1% 
5,9 1 1% 
6,9 2 1% 
7,1 2 1% 
7,10 1 1% 
7,4 2 2% 
7,8 2 2% 
7,9 15 15.30% 
 
1.  Valvular diseases 
2. Interatrial and interventricular shunts 
3. Right ventricular dilation and D shaped interventricular 
septum 
4. Left ventricular diastolic dysfunction 
5. Left ventricular systolic dysfunction EF; 41- 45% 
6. Left ventricular systolic dysfunction EF; 36-40% 
7. Left ventricular systolic dysfunction EF; 30-35% 
8. Regional wall motion abnormality 
9. Global hypokinesia 
10. Pericardial disease 
  
90 
 
2
12
8
6
7
8
10
3
1 1 1 1 1 1
4
1 1
4
1
2 2
1
2 2
15
0
2
4
6
8
10
12
14
16
3 5 7 1,3 1,6 1,8 3,7 4,8 5,4 5,9 7,1 7,4 7,9
ECHO Findings in Study Population 
ECHO
 
 Figure 11  : Showing echo findings in study population  
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Figure 12 : Showing distribution of hemoglobin in study population 
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Figure 13 : Showing distribution of creatinine in study population  
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Figure 14 : Showing distribution of potassium in study population  
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Figure 14 : Showing distribution of urea in study population  
 
 
  
 0
5
10
15
20
25
LV
H
LA
E
15 15
ECG Findings in the Study Population
 
 
Figure 15 : Showing ECG findings in study population 
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Table 12 : Showing ECG findings in study population  
 
ECG finding No. of patients Percentage 
   
LVH 15 15.20% 
LAE 15 15.20% 
PPRW 22 22.30% 
AF 9 9% 
AWMI 12 12.20% 
IWMI 4 4% 
LBBB,LAD 5 5% 
other findings 18 18.30% 
 
LVH- left ventricular hypertrophy 
LAE- left atrial enlargement 
PPRW- poor progression of R wave 
AF- atrial fibrillation 
AWMI- anterior wall myocardial infarction 
IWMI- inferior wall myocardial infarction 
LBBB, LAD- left bundle branch block, left axis deviation 
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DISCUSSION 
 
 This study is a prospective and retrospective observational study 
and was done in Madras Medical college and Rajiv Gandhi government 
general hospital. During the study 100 patients are selected and two 
patients did not give  consent for the study, then 98 patients with the 
diagnosis of cardiac failure who were admitted  earlier in this hospital and 
readmitted within 3 months of discharge were included in the study.  
Informed consent was obtained for the investigations that were required 
during the present admission.  
 The acute heart failure syndrome is one of the major burden of 
hospital admissions. The problem of readmission in cardiac failure 
patients is increasing. About more than half of the patients had coronary 
artery disease and almost half of the patient had valvular heart disease, 
which were correctable causes. Due to lack of infrastructure in a 
developing country like india it makes the treatment impossible even for 
those in whom it is treatable.  Programmes that alter the patient behavior 
towards the disease and modify the risk factors and risk behaviors like 
alcohol intake should be implemented. 
  
98 
 
 
AGE AND HEART FAILURE 
 Our study showed that the heart failure is occurring in relatively 
younger age group than in other studies conducted in various hospitals. 
The Framingham study showed that the incidence and prevalence of  
heart failure increases steeply with age, but in MMC RGGGH 
readmissions were common in the age group of 40 to 54 years . 
 
GENDER  AND HEART FAILURE 
 Vaccarino et al showed women can tolerate heart failure better than 
men because the left ventricular systolic function and high mean arterial 
pressure is better preserved in these patients. Makene et all study showed 
male to female ratio of 1:2.  Our study showed 60% of males and 40% 
females in medical wards. In peripartum cardiomyopathy, 59% of 
patients recover spontaneously, 26% of patients show recurrence in 
subsequent pregnancies, 9% experience progressive dilated 
cardiomyopathy and 11% die  within the first year. In our study only 3 
patients had peripartum cardiomyopathy. 
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AETIOLOGY OF HEART FAILURE 
 As heart failure can involve both the ventricles, it mostly affects 
the left ventricle. Isolated right heart failure does not occur except in cor 
pulmonale. 
Etiology has the following 3 components 
1. Underlying cause 
2. Comorbid illness 
3. Precipitating factor   
 Most common cause in most of the studies is coronary artery 
disease (CAD). In our study CAD tops the list and then follows the 
valvular heart disease. Most common comorbid illness is diabetes 
mellitus which is then followed by anemia and renal failure. Most 
common precipitating factor is lack of compliance towards the drugs and 
then follows lack of fluid and salt restriction. Comorbid illness  do not 
directly attribute to failure, they do by precipitating factor to set in. 
 In a study of home monitoring system dyspnoea and light 
headedness are considered as the common symptoms that has highest 
frequency of readmissions. Anemia is invariably present in all patients.  
 In echocardiogram systolic dysfunction is the most common cause 
for readmission, then follows the  right ventricular dysfunction due to 
valvular heart disease and the diastolic dysfunction. 
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DURATION OF STAY 
 Length of stay in 46% of patients who were admitted during 
previous admissions is within 5 to 10 days. 22.4% percent of patients had 
more than 10 days of stay and 31% of patients had less than 5 days of 
stay. Two patients died in the next admission in whom there was longer 
the length of stay. But the patients who were discharged within 10 days 
experience more frequency of  readmission which  may be due to the 
premature discharge. 
 
SYMPTOM AND READMISSIONS 
 Common presenting symptom is dyspnoea on exertion as most  of 
our patients belong to lower socioeconomic status so they depend on their 
physical abilities to fulfill their daily needs. Orthopnea is the equivalent 
symptom presenting during admission. Patients are enquired about 
number of pillows used during the sleep.  
 
RADIOGRAPHIC FINDINGS 
 37% of patients presented with pulmonary edema grade I by larry 
elliot’s classification. The next common finding  was pulmonary arterial 
hypertension (main pulmonary artery dilatation)  which was observed in 
22.4% of our study population . Bilateral pleural effusion was observed in 
2% of patients. 
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CARDIOVASCULAR EXAMINATION 
 28.9% of our study population had S3 gallop. 8% of patients had 
systolic murmur due to the functional mitral regurgitation. 
 
RESPIRATORY SYSTEM EXAMINATION 
 73.4% of patients of our study population had  basal crepitations 
and few had polyphonic wheeze(cardiac asthma). 
 
ECHOCARDIOGRAM  
 Patients were subjected to echocardiogram within 48 hours of 
admission and  this variable was compared with other studies. In our 
study left ventricular end diastolic volume and left ventricular end 
systolic volume was measured and cut off value was set for each variable. 
These were invariably increased in most of the cardiomyopathies. Most 
of the patients had left ventricular systolic dysfunction which was severe, 
15% had mitral stenosis either alone or associated with other valvular 
involvement. 12% had left ventricular diastolic dysfunction with 
preserved left ventricular systolic function. 
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POOR KNOWLEDGE  
 Each patients were enquired about the nature of the disease and the 
future outcomes by brief questionnaire during the study. The observation 
was that the view about disease progression and the diuretic dose 
adjustment according to congestive symptoms are low in about 40% of  
the patients. 
 As the Indian food preparation contains high amount of sodium, 
the sodium restriction for these patients were also difficult.  
 
LIVER FUNCTION TEST 
 Only 6% of patients showed raise in Bilirubin. These patient had 
symptoms of  congestive hepatitis.  
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CONCLUSION 
 
The inferences drawn from the study are 
 
1. Readmissions are common in the middle age group patients. 
2. Certain diseases like rheumatic valvular heart diseases are 
amenable to surgical correction which can prevent the heart 
failure. 
3. Drugs that decrease the disease progression are not used 
appropriately as there is lack of compliance and awareness 
4. Diabetes mellitus and heart failure commonly are associated in 
many patients 
5. Severe left ventricular systolic dysfunction and diastolic 
dysfunction is the most common echocardiogram finding 
associated with heart failure. 
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ANNEXURES 
 ABBREVIATIONS 
ACC/AHA – American College of Cardiology and  
the American Heart Association 
AHFS – Acute Heart Failure Syndrome 
AT1 – Angiotensin Receptor 1 
ECF – Extracellular Fluid 
ECG – Electrocardiogram 
HFpEF – Heart Failure with Preserved Ejection Fraction 
RAS – Renin Angiotensinogen System 
HF – Heart Failure 
IVC – Inferior Vena Cava 
MRI – Magnetic Resonance Imaging 
NE – Nor Epinephrine 
ET-1 – Endothelin1 
CT – Computerized Tomography 
OSA – Obstructive Sleep Apnea 
SHIFT – Ivabridine and Outcomes in Chronic Heart Failure  
DM – Diabetes Mellitus 
ANP – Atial Natriuretic Peptide 
BNP – Brain Natriuretic Peptide 
ROS – Reactive Oxygen Species 
NYHA – New York Heart Association 
LBBB – Left Bundle Branch Block 
  
PROFORMA 
Causes and Prediction of Readmission of Heart Failure Patients – 
Questionnaire 
 
Name : Patient ID No: 
Age/Sex :  
Socioeconomic status: 
Marital status: 
Occupation: 
Underlying cause 
 Hypertensive heart disease: 
 Ischemic heart disease: 
 Other cardiomyopathies: 
 Valvular heart disease 
Atrial fibrillation or flutter: 
Comorbid illness 
Acute or chronic renal disease: 
Chronic lung disease: 
Diabetes mellitus: 
Anemia: 
Drug or alcohol abuse 
  
Precipitating factor 
lack of compliance 
uncontrolled hypertention 
cardiac arrhythmias 
inadequate therapy 
pulmonary infection 
emotional stress 
inappropriate medication or fluid overload 
myocardial infarction 
endocrine disorders 
Duration of stay : 
General examination  
Systemic examination  
CVS:    
RS:    
P/A:   
CNS: 
  
Investigations : 
ECG  
Echocardiogram 
Chest x ray 
Thyroid function test 
Complete blood count 
Blood biochemistry 
Serum electrolytes  
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INFORMATION SHEET 
 
We are conducting a study on “causes and prediction of 
readmissions of heart failure patients” among patients attending Rajiv 
Gandhi Government General Hospital, Chennai and for that your 
specimen may be valuable to us. 
The purpose of this study is to asses the“causes and prediction of 
readmissions of heart failure patients”   and We are selecting certain 
cases and if you are found eligible physical examination done. 5ml blood 
will be collected and 2ml of urine will be collected. You will also 
echocardiogram, electrocardiogram, chest xray. These tests and special 
studies do not affect your final report or management. 
The privacy of the patients in the research will be maintained 
sthroughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will be 
shared. 
Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are otherwise 
entitled. 
The results of the special study may be intimated to you at the end 
of the study period or during the study if anything is found abnormal 
which may aid in the management or treatment. 
 
 
Signature of Investigator            Signature of Participant  
PATIENT CONSENT FORM 
Study title : Causes and prediction of readmissions of heart 
failure patients 
Study Centre : Rajiv Gandhi Government General Hospital, 
Chennai. 
Name :  
Age/Sex :  
Identification 
Number 
:  
Patient may check (☑) these boxes 
The details of the study have been provided to me in writing and 
explained to me in my own language ❏ 
I understand that my participation in the study is voluntary and that I 
am free to withdraw at any time without giving reason, without 
my legal rights being affected. ❏ 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory 
authorities will not need my permission to look at my health 
records, both in respect of current study and any further research ❏ 
that may be conducted in relation to it, even if I withdraw from 
the study I agree to this access. However, I understand that my 
identity will not be revealed in any information released to third 
parties or published, unless as required under the law. I agree not 
to restrict the use of any data or results that arise from this study. 
I agree to take part in the above study and to comply with the 
instructions given during the study and faithfully cooperate with 
the study team and to immediately inform the study staff if I 
suffer from any deterioration in my health or wellbeing or any 
unexpected or unusual symptoms. ❏ 
I hereby consent to participate in this study. ❏ 
I hereby give permission to undergo complete clinical examination 
and diagnostic tests including hematological and biochemical 
tests. ❏ 
 
Signature/thumb impression 
Patient’s Name and Address: 
Signature of Investigator 
Study Investigator’s Name: 
Dr.J SUDHA MALLIKA 
Name 
Ip No 
Sex 
Age 
Underlying 
Cause 
Comorbid 
Illness 
Precipitating 
Factor 
Duration Of 
Stay 
Cvs 
Rs 
Examination 
Ecg 
Echo 
Chest X Ray 
Hemoglobin 
Urea 
Creatinine 
Sodium 
Pottasium 
Total 
Billirubin 
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1,
2 
3 
1 
2 
1 
1 
QS
 
co
m
pl
ex
 
v
1 
to
 
v
4,
 
7 
1 
8.
9 
39
 
1 
12
8 
4.
3 
1 
N
ag
am
m
al
 
88
88
4 
2 
40
 
4,
5 
 
 
2 
 
1 
rig
ht
 
ax
is 
de
v
ia
tio
n
 
w
ith
 
rig
ht
 
an
d 
le
ft 
at
ria
l e
n
la
rg
e
m
en
t 
1,
3 
6 
9.
9 
42
 
1.
3 
13
5 
3.
2 
1.
2 
Pa
rv
at
hy
 
87
69
5 
2 
61
 
2 
 
8 
1 
2 
1 
le
ft 
at
ria
l e
n
la
rg
e
m
en
t 
6 
5 
10
.
2 
32
 
1.
5 
13
5 
2.
8 
1 
R
ad
ha
 
88
40
6 
2 
58
 
1,
2 
3 
 
3 
 
1 
ST
 
se
gm
en
t e
le
v
at
io
n
 
v
1 
to
 
v
4 
4,
8 
1 
8.
8 
16
 
0.
9 
13
9 
3.
4 
0.
7 
K
an
n
iy
am
m
al
 
88
26
5 
2 
55
 
4,
5 
 
7 
1 
 
1 
at
ria
l f
ib
ril
la
tio
n
 
w
ith
 
rig
ht
 
ax
is 
de
v
ia
tio
n
 
1,
3 
6 
9.
7 
27
 
1 
14
0 
4 
1 
V
io
le
t 
89
85
1 
2 
40
 
4 
4 
3 
3 
 
1 
at
ria
l f
ib
ril
la
tio
n
 
w
ith
 
rig
ht
 
ax
is 
de
v
ia
tio
n
 
1,
3 
6 
11
 
30
 
0.
8 
14
2 
4.
2 
4 
B
u
v
an
es
w
ar
i 
89
11
5 
2 
36
 
4,
5 
 
 
2 
1 
1 
st
 
se
gm
en
t e
le
v
at
io
n
 
v
1 
to
 
v
4 
1,
3 
6 
11
.
1 
43
 
1.
4 
13
2 
4.
4 
1 
V
al
li 
88
15
0 
2 
40
 
4 
4 
 
1 
 
1 
rig
ht
 
ax
is 
de
v
ia
tio
n
 
w
ith
 
rig
ht
 
an
d 
le
ft 
at
ria
l e
n
la
rg
e
m
en
t 
1,
3 
6 
10
.
5 
10
.
5 
0.
9 
14
1 
4.
3 
0.
9 
A
n
bu
m
an
i 
81
43
7 
1 
56
 
2 
 
 
3 
 
1 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
fro
m
 
v
1 
to
 
v
6 
5 
5 
11
.
1 
30
 
1 
13
8 
4.
1 
0.
8 
M
ar
u
dh
am
u
th
u
 
81
24
6 
1 
80
 
1,
2 
1 
 
2 
2 
1 
QS
 
co
m
pl
ex
 
v
1 
to
 
v
4,
 
6 
2 
8 
56
 
2.
1 
14
0 
5.
5 
0.
9 
A
lg
ap
pa
n
 
78
77
1 
1 
64
 
2 
 
5 
1 
1 
1 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
fro
m
 
v
1 
to
 
v
6 
7 
1 
11
.
2 
28
 
1.
2 
14
0 
3.
4 
0.
8 
Pe
ru
m
al
 
78
74
0 
1 
46
 
2 
2 
 
3 
 
1 
le
ft 
ax
is 
de
v
ia
tio
n
,
 
le
ft 
at
ria
l e
n
la
rg
em
en
t 
5 
1 
12
 
30
 
1 
13
5 
4 
1 
Se
lv
ar
aj 
78
49
7 
1 
65
 
1,
2 
3 
6 
1 
2 
1 
le
ft 
v
en
tr
ic
u
la
r 
hy
pe
rt
ro
ph
y 
w
ith
 
st
ra
in
 
pa
tte
rn
 
6 
2 
13
 
54
 
1.
8 
13
6 
3.
8 
2.
6 
La
ks
hm
an
an
 
76
14
8 
1 
32
 
2 
1 
7 
2 
 
1 
t w
av
e 
in
v
er
tio
n
 
w
ith
 
q 
w
av
es
 
in
 
v
1 
to
 
v
4 
8 
1 
6.
7 
21
2 
5 
14
6 
5.
5 
1.
3 
Se
lv
am
 
86
55
1 
1 
45
 
1,
2 
3 
1 
2 
 
1 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
fro
m
 
v
1 
to
 
v
6 
7 
2 
16
.
9 
23
 
1 
14
0 
4 
1 
G
o
pi
 
55
05
4 
1 
60
 
2 
 
 
2 
1 
1 
QS
 
co
m
pl
ex
 
v
1 
to
 
v
4,
 
7,
9 
3 
14
 
56
 
2 
13
8 
3.
8 
0.
7 
M
eg
an
ad
ha
n
 
49
68
4 
1 
62
 
2 
 
8 
3 
 
1,
2 
le
ft 
v
en
tr
ic
u
la
r 
hy
pe
rt
ro
ph
y 
w
ith
 
st
ra
in
 
pa
tte
rn
 
7,
9 
2 
11
.
8 
64
 
1.
8 
13
6 
3.
6 
0.
8 
V
ar
ad
ha
ra
m
an
u
jam
 
47
19
4 
1 
75
 
1 
1,
3 
 
3 
1 
1,
2 
le
ft 
ax
is 
de
v
ia
tio
n
,
 
le
ft 
at
ria
l e
n
la
rg
em
en
t 
7,
9 
3 
10
.
9 
44
 
1 
13
3 
3.
5 
0.
9 
El
u
m
al
ai
 
86
87
0 
1 
85
 
2 
 
8 
3 
 
1 
le
ft 
v
en
tr
ic
u
la
r 
hy
pe
rt
ro
ph
y 
w
ith
 
st
ra
in
 
pa
tte
rn
 
5,
 
1 
11
.
5 
27
 
1 
14
1 
4.
3 
1 
V
el
an
 
87
72
4 
1 
44
 
1 
1,
3 
1 
2 
2 
1 
le
ft 
ax
is 
de
v
ia
tio
n
,
 
le
ft 
at
ria
l e
n
la
rg
em
en
t 
4 
8 
10
 
10
8 
4.
1 
12
1 
5.
2 
1.
2 
D
u
ra
isa
m
y 
87
80
1 
1 
52
 
1,
2 
1 
7 
1 
 
1 
QS
 
co
m
pl
ex
 
v
1 
to
 
v
4,
 
7 
1 
9.
8 
10
5 
2.
9 
14
0 
3.
3 
1.
1 
Sa
ra
v
an
an
 
86
61
1 
1 
40
 
4,
5 
1 
 
3 
 
1 
le
ft 
v
en
tr
ic
u
la
r 
hy
pe
rt
ro
ph
y 
w
ith
 
st
ra
in
 
pa
tte
rn
 
4 
6 
9 
21
1 
2.
2 
12
4 
3.
5 
1 
K
u
pp
an
 
86
55
9 
1 
59
 
1 
3 
 
3 
1 
1 
QS
 
co
m
pl
ex
 
v
1 
to
 
v
4,
 
7,
9 
8 
8 
47
 
2.
6 
13
8 
4.
7 
1.
3 
Ch
ris
to
ph
ar
 
88
59
2 
1 
59
 
2 
1 
 
2 
1 
1 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
fro
m
 
v
1 
to
 
v
6,
 
an
d 
le
ft 
at
ria
l e
n
la
rg
e
m
en
t 
7,
9 
1 
14
.
3 
25
 
1.
1 
14
0 
4 
2 
A
so
ka
n
 
85
38
5 
1 
60
 
3 
1 
1 
2 
 
1,
2 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
fro
m
 
v
1 
to
 
v
6 
7 
1 
11
 
30
 
1 
13
8 
3.
8 
0.
9 
Ch
an
dr
as
ek
ar
 
86
25
4 
1 
47
 
3 
3 
 
1 
 
1 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
fro
m
 
v
1 
to
 
v
6 
5,
1o
 
3 
10
.
2 
32
 
1.
3 
14
0 
4 
1 
Name 
Ip No 
Sex 
Age 
Underlying 
Cause 
Comorbid 
Illness 
Precipitating 
Factor 
Duration Of 
Stay 
Cvs 
Rs 
Examination 
Ecg 
Echo 
Chest X Ray 
Hemoglobin 
Urea 
Creatinine 
Sodium 
Pottasium 
Total 
Billirubin 
M
u
ru
ga
n
 
83
63
7 
1 
53
 
1 
 
1 
1 
 
 
le
ft 
v
en
tr
ic
u
la
r 
hy
pe
rt
ro
ph
y 
w
ith
 
st
ra
in
 
pa
tte
rn
 
4,
5 
1 
11
 
30
 
1 
13
2 
2.
3 
1 
V
ija
ya
n
 
82
25
3 
1 
65
 
1,
2 
 
1 
1 
 
 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
fro
m
 
v
1 
to
 
v
6 
5,
8 
1 
13
 
28
 
0.
8 
14
0 
3.
2 
0.
9 
M
an
i 
87
03
3 
1 
56
 
2 
 
7 
2 
1 
1 
bi
fa
sc
ic
u
la
r 
bl
o
ck
 
7,
9 
1 
10
.
2 
28
 
1.
07
 
14
0 
6.
3 
0.
8 
M
o
o
rt
hy
 
86
68
0 
1 
45
 
4 
 
1 
1 
1 
1 
at
ria
l f
ib
ril
la
tio
n
 
7,
9 
6 
10
.
4 
65
 
1.
4 
13
4 
6.
5 
1 
A
m
m
u
 
86
63
3 
2 
35
 
2 
4 
 
2 
 
1 
rig
ht
 
ax
is 
de
v
ia
tio
n
 
w
ith
 
rig
ht
 
an
d 
le
ft 
at
ria
l e
n
la
rg
e
m
en
t 
8 
2 
11
 
30
 
1 
13
6 
4 
1.
6 
Pa
rv
at
hi
 
87
71
0 
2 
61
 
2 
 
 
1 
 
 
le
ft 
ax
is 
de
v
ia
tio
n
,
 
le
ft 
at
ria
l e
n
la
rg
em
en
t, 
in
tr
av
en
tr
ic
u
la
r 
co
n
du
ct
io
n
 
bl
o
ck
 
8 
1 
10
.
5 
23
 
1 
13
6 
5.
5 
1.
2 
K
an
n
iy
am
m
a 
 
87
81
1 
2 
45
 
4 
 
5,
7 
1 
 
 
do
u
bl
e 
qr
s 
co
m
pl
ex
es
,
 
hi
m
al
ay
an
 
p 
w
av
e 
10
 
7 
9.
7 
32
 
1.
5 
13
9 
4.
9 
1 
M
ee
n
a 
87
56
7 
2 
35
 
4,
5 
 
3 
3 
 
1 
rig
ht
 
ax
is 
de
v
ia
tio
n
,
 
at
ria
l f
ib
ril
la
tio
n
 
1,
3 
6 
13
 
42
 
0.
8 
14
0 
5 
1 
A
ru
m
u
ga
m
 
87
71
7 
1 
48
 
2 
 
7 
2 
1 
1 
le
ft 
ax
is 
de
v
ia
tio
n
 
w
ith
 
le
ft 
an
te
rio
r 
fa
sc
ic
u
la
r 
bl
o
ck
,
 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
5 
1 
11
.
5 
65
 
1.
2 
13
7 
5 
0.
9 
D
ha
n
as
ek
ar
 
85
55
6 
1 
40
 
1 
3 
 
1 
 
1 
le
ft 
ax
is 
de
v
ia
tio
n
 
,
 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
7,
10
 
1 
10
 
26
 
1.
4 
14
6 
6 
0.
8 
R
as
u
 
87
75
3 
1 
63
 
1,
2 
3 
 
2 
 
 
le
ft 
ax
is 
de
v
ia
tio
n
 
,
 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
6 
8 
12
.
4 
17
 
1 
14
0 
3.
2 
2 
Y
as
ho
da
m
m
al
 
87
69
5 
2 
80
 
1,
2 
 
 
2 
 
 
le
ft 
ax
is 
de
v
ia
tio
n
 
w
ith
 
le
ft 
an
te
rio
r 
fa
sc
ic
u
la
r 
bl
o
ck
,
 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
8 
1 
11
.
6 
15
 
1.
2 
14
7 
4.
3 
1 
V
an
aja
 
87
23
1 
2 
63
 
2 
3 
 
1 
 
1 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
fro
m
 
v
1 
to
 
v
6 
7,
9 
1 
7.
4 
49
 
1.
3 
12
6 
4.
3 
0.
9 
M
u
ru
ga
n
 
87
19
8 
1 
46
 
2 
3 
 
2 
 
1 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
fro
m
 
v
1 
to
 
v
6 
8 
1 
11
 
30
 
0.
9 
13
0 
4 
0.
8 
Sa
ra
su
 
87
39
8 
2 
60
 
3 
 
1 
2 
1 
1 
in
co
m
pl
et
e 
R
B
BB
,
 
rig
ht
 
ax
is 
de
v
ia
tio
n
 
2,
3 
7 
12
 
15
 
0.
8 
13
8 
4.
1 
1 
A
m
ar
av
at
hy
 
86
96
6 
2 
75
 
2 
 
 
1 
 
 
rig
ht
 
ax
is 
de
v
ia
tio
n
 
w
ith
 
rig
ht
 
bu
n
dl
e 
br
an
ch
 
bl
o
ck
 
3 
2 
12
.
5 
16
 
0.
6 
12
1 
4 
1 
M
ar
ia
m
m
al
 
86
54
7 
2 
55
 
2 
3 
 
1 
 
1 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
fro
m
 
v
1 
to
 
v
5 
8 
1 
11
.
1 
47
 
1.
3 
13
0 
4.
2 
0.
8 
Su
se
el
a 
86
99
8 
2 
47
 
2 
3 
1,
7 
1 
 
 
le
ft 
v
en
tr
ic
u
la
r 
hy
pe
rt
ro
ph
y 
w
ith
 
st
ra
in
 
pa
tte
rn
 
5,
 
1 
8.
9 
26
 
0.
9 
13
6 
3.
5 
0.
9 
Je
ev
ar
at
hi
n
am
 
85
67
3 
1 
55
 
2,
4 
3 
 
2 
 
1 
le
ft 
v
en
tr
ic
u
la
r 
hy
pe
rt
ro
ph
y 
w
ith
 
st
ra
in
 
pa
tte
rn
 
1,
4 
6 
9.
2 
63
 
1.
2 
14
0 
4.
1 
0.
8 
A
m
m
ap
o
n
n
u
 
86
79
0 
2 
63
 
4,
5 
 
 
1 
2 
1 
le
ft 
v
en
tr
ic
u
la
r 
hy
pe
rt
ro
ph
y 
w
ith
 
st
ra
in
 
pa
tte
rn
,
 
rig
ht
 
v
en
tr
ic
u
la
r 
hy
pe
rt
ro
ph
y 
1,
4 
6 
7.
4 
56
 
1.
1 
13
0 
5 
2 
G
an
ga
dh
ar
an
 
85
56
0 
2 
45
 
2 
3 
 
2 
1 
 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
fro
m
 
v
1 
to
 
v
4 
7,
9 
1 
9 
30
 
0.
6 
13
4 
4 
0.
9 
U
m
as
an
ka
r 
79
48
5 
1 
45
 
2 
 
6 
2 
1 
1 
le
ft 
an
te
rio
r 
fa
sc
ic
u
la
r 
bl
o
ck
,
 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
7,
9 
8 
11
.
2 
27
 
1.
1 
13
0 
4.
1 
1 
Sa
ra
v
an
an
 
82
23
3 
1 
37
 
1,
2 
1,
3 
 
2 
 
1 
le
ft 
ax
is 
de
v
ia
tio
n
 
w
ith
 
po
o
r 
pr
o
gr
es
sio
n
 
o
f 
6,
9 
1 
7.
8 
89
 
4.
6 
14
3 
4 
0.
7 
Ba
la
kr
ish
n
an
 
87
15
0 
1 
74
 
3 
 
1,
7 
1 
 
 
le
ft 
ax
is 
de
v
ia
tio
n
 
w
ith
 
rig
ht
 
bu
n
dl
e 
br
an
ch
 
bl
o
ck
,
 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
7,
8 
2 
12
.
6 
27
 
1 
14
5 
4.
1 
0.
8 
Sa
th
ik
 
87
09
5 
1 
68
 
3 
2 
1,
7 
1 
1 
1 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
7,
9 
3 
12
.
4 
27
 
0.
9 
14
3 
3.
3 
0.
9 
M
u
ru
ga
n
 
87
15
9 
1 
46
 
2 
 
4 
2 
 
1 
le
ft 
ax
is 
de
v
ia
tio
n
,
 
le
ft 
at
ria
l e
n
la
rg
em
en
t, 
in
tr
av
en
tr
ic
u
la
r 
co
n
du
ct
io
n
 
bl
o
ck
 
7,
8 
2 
14
 
31
 
1 
14
0 
4 
1 
Name 
Ip No 
Sex 
Age 
Underlying 
Cause 
Comorbid 
Illness 
Precipitating 
Factor 
Duration Of 
Stay 
Cvs 
Rs 
Examination 
Ecg 
Echo 
Chest X Ray 
Hemoglobin 
Urea 
Creatinine 
Sodium 
Pottasium 
Total 
Billirubin 
D
u
ra
ira
j 
86
78
1 
1 
53
 
2 
3 
 
1 
 
 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
4,
8 
1 
10
.
1 
24
 
1.
1 
14
3 
4.
1 
2.
4 
U
n
n
a
m
al
ai
 
81
25
1 
2 
67
 
2 
3 
 
1 
 
1 
le
ft 
ax
is 
de
v
ia
tio
n
 
w
ith
 
rig
ht
 
bu
n
dl
e 
br
an
ch
 
bl
o
ck
,
 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
4,
8 
1 
12
.
6 
30
 
1.
1 
13
8 
3.
6 
1 
V
en
ka
te
sh
 
86
67
7 
1 
52
 
1,
2 
 
1,
7 
2 
 
1 
le
ft 
v
en
tr
ic
u
la
r 
hy
pe
rt
ro
ph
y 
w
ith
 
st
ra
in
 
pa
tte
rn
,
 
rig
ht
 
v
en
tr
ic
u
la
r 
hy
pe
rt
ro
ph
y 
4 
1 
10
.
4 
30
 
0.
9 
13
2 
6 
1 
Th
an
ga
ra
j 
87
25
0 
1 
40
 
2 
5 
 
2 
 
1 
rig
ht
 
bu
n
dl
e 
br
an
ch
 
bl
o
ck
 
5,
9 
8 
10
.
7 
58
 
2.
6 
13
6 
4.
1 
0.
8 
Su
br
am
an
i 
87
25
2 
1 
36
 
2 
 
 
3 
1 
1 
le
ft 
ax
is 
pr
o
gr
es
sio
n
 
,
 
q 
w
av
e 
in
 
le
ad
 
II
,
 
III
,
 
aV
F 
7,
9 
3 
9.
2 
43
 
1 
12
3 
4 
1 
Y
o
ga
m
m
al
 
85
67
5 
2 
50
 
2,
4 
3 
 
2 
 
1 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
7,
1 
6 
12
.
4 
63
 
1.
2 
14
0 
5.
6 
0.
9 
D
ha
n
as
ek
ar
an
 
85
55
6 
1 
40
 
1,
2 
3 
 
2 
1 
1 
le
ft 
at
ria
l e
n
la
rg
e
m
en
t,l
ef
t a
n
te
rio
r 
fa
sc
ic
u
la
r 
bl
o
ck
,
 
po
o
r 
pr
o
gr
es
sio
n
 
o
f r
 
w
av
e 
7,
9 
3 
11
 
17
 
1 
14
0 
3.
2 
0.
8 
Ba
la
ra
m
an
 
85
43
5 
1 
58
 
4 
 
 
2 
 
 
le
ft 
at
ria
l e
n
la
rg
e
m
en
t, 
le
ft 
v
en
tr
ic
u
la
r 
st
ra
in
 
pa
tte
rn
 
7,
1 
2 
10
.
4 
10
9 
2 
14
0 
5.
5 
0.
9 
M
an
ik
a
m
m
al
 
85
49
6 
2 
58
 
3 
3 
8 
1 
 
 
le
ft 
ax
is 
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Key to Master Chart 
SEX: 
Male – 1 
Female – 2 
UDERLYING CAUSES 
Hypertensive heart disease -1 
Ischemic heart disease-2 
Other cardiomyopathies-3 
Valvular heart disease-4 
Atrial fibrillation or flutter-5 
 COMORBID ILLNESS 
Acute or chronic renal disease-1 
 Chronic lung disease:-2 
 Diabetes mellitus:-3 
 Anemia:-4 
Drug or alcohol abuse-5 
 PRECIPITATING FACTOR 
1. lack of compliance 
2. uncontrolled hypertention 
3. cardiac arrhythmias 
4. inadequate therapy 
5. pulmonary infection 
6. emotional stress 
7. inappropriate medication or fluid overload 
8. myocardial infarction 
9. endocrine disorders 
DURATION OF STAY 
1. 1-4 days 
2. 5-9 days 
3. >10 days 
CARDIOVASCULAR SYSTEM AUSCULTATION 
1. S3 heard 
2. Systolic murmur heard 
RESPIRATORY SYSTEM AUSCULTATION 
1. Basal crepitations 
2. Wheeze 
ECHOCARDIOGRAM 
1. Valvular disease 
2. Interatrial and interventricular shunts 
3. Right ventricular dilation and D shaped interventricular septum 
4. Left ventricular diastolic dysfunction 
5. Left ventricular systolic dysfunction EF; 41- 45% 
6. Left ventricular systolic dysfunction EF; 36-40% 
7. Left ventricular systolic dysfunction EF; 30-35% 
8. Regional wall motion abnormality 
9. Global hypokinesia 
10. Pericardial disease 
N; CHEST X RAY 
1. Pulmonary hypertension grade I according to larry Elliot’s classification upper 
lobe veins prominent 
2. Grade II either kerley A,B,C lines or hilar haziness 
3. GradeIII- bilateral patchy opacities 
4. Grade IV- bilateral milliary mottling 
5. Pleural effusion 
6. postcapillary pulmonary arterial hypertension showing main pulmonary artery 
dilation 
7. precapillary pulmonary arterial hypertension 
8. normal lung field 
9. suggestive of COPD 
BILLIRUBIN 
1. Elevated 
2. Not Elevated 
 
